Literature DB >> 15753655

Connecting reovirus oncolysis and Ras signaling.

Paola Marcato1, Maya Shmulevitz, Patrick W Lee.   

Abstract

Reovirus is a benign virus with innate oncolytic activity and is a potential novel therapeutic for a number of cancers. Reovirus can replicate in, and induce death of cancerous cells having an activated Ras pathway. Ras activation leads to the inactivation of cellular antiviral mechanisms, specifically removing the translation block on reovirus transcripts. This review outlines recent progress towards elucidating the molecular connection between the Ras-signaling pathway and reovirus replication.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15753655     DOI： 10.4161/cc.4.4.1600

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


  19 in total

1.  Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague-Dawley rats.

Authors:  Romit Chakrabarty; Hue Tran; Iohann Boulay; Tanya Moran; Audrey Parenteau; Robert Tavcar; Maude Bigras; Allison Hagerman; Sarah Serl; Brad Thompson; Matt Coffey
Journal:  Invest New Drugs       Date:  2013-12       Impact factor: 3.850

2.  The oncolytic efficacy and safety of avian reovirus and its dynamic distribution in infected mice.

Authors:  Ruimin Cai; Guangyuan Meng; Yi Li; Wenyang Wang; Youxiang Diao; Shuping Zhao; Qiang Feng; Yi Tang
Journal:  Exp Biol Med (Maywood)       Date:  2019-07-12

3.  Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D.

Authors:  Niels Smakman; Diana J M van den Wollenberg; Inne H M Borel Rinkes; Rob C Hoeben; Onno Kranenburg
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 4.  The oncolytic virus, pelareorep, as a novel anticancer agent: a review.

Authors:  Romit Chakrabarty; Hue Tran; Giovanni Selvaggi; Allison Hagerman; Brad Thompson; Matt Coffey
Journal:  Invest New Drugs       Date:  2015-02-19       Impact factor: 3.850

5.  Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.

Authors:  Marianne M Stanford; John W Barrett; Steven H Nazarian; Steven Werden; Grant McFadden
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

6.  Oncolytic virus-initiated protective immunity against prostate cancer.

Authors:  Shashi A Gujar; D A Pan; Paola Marcato; Katy A Garant; Patrick W K Lee
Journal:  Mol Ther       Date:  2011-01-18       Impact factor: 11.454

7.  Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.

Authors:  F Errington; C L White; K R Twigger; A Rose; K Scott; L Steele; L J Ilett; R Prestwich; H S Pandha; M Coffey; P Selby; R Vile; K J Harrington; A A Melcher
Journal:  Gene Ther       Date:  2008-04-10       Impact factor: 5.250

8.  Reovirus uses multiple endocytic pathways for cell entry.

Authors:  Wade L Schulz; Amelia K Haj; Leslie A Schiff
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

9.  Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming.

Authors:  Lynette Steele; Fiona Errington; Robin Prestwich; Elizabeth Ilett; Kevin Harrington; Hardev Pandha; Matt Coffey; Peter Selby; Richard Vile; Alan Melcher
Journal:  Mol Cancer       Date:  2011-02-21       Impact factor: 27.401

10.  Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor.

Authors:  J-C Tseng; T Granot; V DiGiacomo; B Levin; D Meruelo
Journal:  Cancer Gene Ther       Date:  2009-10-02       Impact factor: 5.987
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.